Investigatio quadrigis ab Abramson Cancer Centre (ACC) in Universitate Scholae Medicinae Pennsylvania inventa est utrum tumor calidus an frigidus sit per informationes in cellulas cancri infixas constitutas esse. “Hot” tumors are often considered more sensitive to immunotherapy. In a new study published this week in Immunity, the researchers explored the role of “tumor heterogeneity”, namely the ability of tumor cells to move, replicate, metastasize and respond to treatment. These new findings can help oncologists more accurately tailor the unique tuberculum composition of patients.
Ben Stanger, et doctor in cellula gastroenterology et developmental biology cum University of Pennsylvania Perelman nisl, dixerunt, quod ex quo gradus ad T cellulis et conputrescebant prominentes nundinari solent modificatur ex tumore Utilia genes. Ut crescere ani aurei, quod necesse est impetus ne per immune ratio. Sunt duo vias: ut develop in secretiori parte natium frigida, vel calida stercora digeruntur potest deplete T cellulis a damnum ut tumore cellulis protegens valet patientes estote immune ratio.
In this study, researchers found that whether a tumor is hot or cold determines whether it will respond to immunotherapy. Cold tumor cells produce a compound called CXCL1, which can instruct bone marrow cells to enter the tumor, keep T cells away from the tumor, and ultimately make the immunotherapy insensitive. In contrast, knocking out CXCL1 in cold tumors promotes T cell infiltration and sensitivity to immunotherapy.
Bigas generatae seriem cellula acidis imitantur vitea lineae, quae habet ductum pancreaticum tumores, inter exercitii varietates tendebant ad eos continere immune cellulis. In posterum, his cellula lineae potest auxilium tumor adhuc identify specifica, et ad optimize cuique curatio de patientibus tumor Heterogenei Luminis variis civitatibus.
